Search

Your search keyword '"B. Trumbic"' showing total 25 results
Start Over Author "B. Trumbic"
25 results on '"B. Trumbic"'

1. Atteinte pulmonaire du déficit en alpha-1 antitrypsine. Recommandations pratiques pour le diagnostic et la prise en charge

Author

J.-F. Mornex, M. Balduyck, M. Bouchecareilh, A. Cuvelier, R. Epaud, M. Kerjouan, O. Le Rouzic, C. Pison, L. Plantier, M.-C. Pujazon, M. Reynaud-Gaubert, A. Toutain, B. Trumbic, M.-C. Willemin, M. Zysman, O. Brun, M. Campana, F. Chabot, V. Chamouard, M. Dechomet, J. Fauve, B. Girerd, C. Gnakamene, S. Lefrançois, J.-N. Lombard, B. Maitre, C. Maynié-François, A. Moerman, A. Payancé, P. Reix, D. Revel, M.-P. Revel, M. Schuers, P. Terrioux, D. Theron, F. Willersinn, V. Cottin, and H. Mal

Subjects
Pulmonary and Respiratory Medicine
Published
2022
Full Text
View/download PDF

3. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version courte

Author

V. Cottin, P. Bonniaud, J. Cadranel, B. Crestani, S. Jouneau, S. Marchand-Adam, H. Nunes, L. Wémeau-Stervinou, E. Bergot, E. Blanchard, R. Borie, A. Bourdin, C. Chenivesse, A. Clément, E. Gomez, A. Gondouin, S. Hirschi, F. Lebargy, C.-H. Marquette, D. Montani, G. Prévot, S. Quetant, M. Reynaud-Gaubert, M. Salaun, O. Sanchez, B. Trumbic, K. Berkani, P.-Y. Brillet, M. Campana, L. Chalabreysse, G. Chatté, D. Debieuvre, G. Ferretti, J.-M. Fourrier, N. Just, M. Kambouchner, B. Legrand, F. Le Guillou, J.-P. Lhuillier, A. Mehdaoui, J.-M. Naccache, C. Paganon, M. Rémy-Jardin, S. Si-Mohamed, P. Terrioux, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de Pneumologie et Allergie - Hôpital Nord [Marseille], Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, du Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), and Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)

Subjects
Pulmonary and Respiratory Medicine, [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022
Full Text
View/download PDF

4. Management of pain associated with up-to-9-weeks medical termination of pregnancy (MToP) using mifepristone–misoprostol regimens: expert consensus based on a systematic literature review

Author

Aubert Agostini, Christian Fiala, Sharon Cameron, K Gemzell Danielsson, B. Trumbic, Mirella Parachini, Laurence Saya, Roberto Lertxundi, Teresa Bombas, and Marek Lubusky

Subjects
medicine.medical_specialty, Consensus, medicine.medical_treatment, Ibuprofen, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, Humans, Pain Management, Medicine, Intensive care medicine, Misoprostol, Pain Measurement, 030219 obstetrics & reproductive medicine, business.industry, Abortifacient Agents, Steroidal, Anti-Inflammatory Agents, Non-Steroidal, Obstetrics and Gynecology, Expert consensus, Abortion, Induced, Mifepristone, medicine.disease, Medical abortion, Clinical trial, Pregnancy Trimester, First, Systematic review, 030220 oncology & carcinogenesis, Female, business, medicine.drug
Abstract

Evidence-based guidelines on the management of pain associated with first-trimester medical abortion are lacking. Most published clinical trials have failed to report on this important aspect of the procedure. The aim of this comprehensive work was to provide clinical advice based on a comprehensive literature review, supplemented by the clinical experience of a group of European experts in case no evidence is available. Pain level ranged from 5 to 8 in 80% of studies where pain was measured on a 0–10 visual analogue scale; severe pain was reported by 20–80% of women. Pain assessment was rarely reported in studies. Pain treatment should be preventive and avoidance of unnecessary uterine contractions should be considered. Analgesic treatment should follow the WHO three-step ladder, starting with the use of NSAIDs and allowing for easily available back-up treatment with weak opioids.

Published
2019
Full Text
View/download PDF

5. [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. 2017 update. Full-length update]

Author

V, Cottin, B, Crestani, J, Cadranel, J-F, Cordier, S, Marchand-Adam, G, Prévot, B, Wallaert, E, Bergot, P, Camus, J-C, Dalphin, C, Dromer, E, Gomez, D, Israel-Biet, S, Jouneau, R, Kessler, C-H, Marquette, M, Reynaud-Gaubert, B, Aguilaniu, D, Bonnet, P, Carré, C, Danel, J-B, Faivre, G, Ferretti, N, Just, F, Lebargy, B, Philippe, P, Terrioux, F, Thivolet-Béjui, B, Trumbic, and D, Valeyre

Published
2017

6. [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis: 2017 update. Short-length version]

Author

V, Cottin, B, Crestani, J, Cadranel, J-F, Cordier, S, Marchand-Adam, G, Prévot, B, Wallaert, E, Bergot, P, Camus, J-C, Dalphin, C, Dromer, E, Gomez, D, Israel-Biet, S, Jouneau, R, Kessler, C-H, Marquette, M, Reynaud-Gaubert, B, Aguilaniu, D, Bonnet, P, Carré, C, Danel, J-B, Faivre, G, Ferretti, N, Just, F, Lebargy, B, Philippe, P, Terrioux, F, Thivolet-Béjui, B, Trumbic, and D, Valeyre

Published
2017

7. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. Élaborées par le centre national de référence et les centres de compétence pour les maladies pulmonaires rares sous l’égide de la Société de pneumologie de langue française [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. 2017 update. Full-length update]

Author

Emmanuel Bergot, Gilbert Ferretti, D. Bonnet, Sylvain Marchand-Adam, Jacques Cadranel, Philippe Carré, Dominique Israel-Biet, Claire Dromer, P. Terrioux, Dominique Valeyre, Charles-Hugo Marquette, Françoise Thivolet-Béjui, Vincent Cottin, G. Prévot, Bruno Crestani, J.-C. Dalphin, Jean-François Cordier, Martine Reynaud-Gaubert, Ronald C. Kessler, Claire Danel, Emmanuel Gomez, B. Trumbic, François Lebargy, Jean-Baptiste Faivre, Philippe Camus, Bernard Aguilaniu, B. Philippe, Stéphane Jouneau, N. Just, Benoit Wallaert, Cadieu, Muriel, Service de Pneumologie, Centre de Référence National des Maladies Pulmonaires Rares, Hospices Civils de Lyon (HCL), Centre de compétences pour les maladies pulmonaires rares, Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université d'Angers (UA)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Pulmonary and Respiratory Medicine, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 030212 general & internal medicine, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 3. Good health
Abstract

National audience; La fibrose pulmonaire idiopathique (FPI) est la forme la plus fréquente de pneumopathie interstitielle diffuse (PID) idiopathique chronique chez l’adulte. Il s’agit d’une maladie fibroproliférative, irréversible, de cause inconnue, dont l’évolution est habituellement progressive, survenant principalement à partir de 60 ans et limitée aux poumons. Qualifiée de maladie orpheline notamment en raison de l’absence de traitement ayant fait la preuve formelle de son efficacité jusqu’à une période très récente, la FPI est une maladie rare dont la prévalence a été évaluée aux États-Unis entre 14 et 28/100 000 personnes [1], ce qui correspondrait à un minimum de 9000 patients en France et une incidence entre 6,8 et 9/100 000 par an [1,2], soit un minimum de 4400 nouveaux patients par an en France.

Published
2017
Full Text
View/download PDF

8. RETRAIT : Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique : actualisation 2017. Résumé

Author

V. Cottin, B. Crestani, J. Cadranel, J.-F. Cordier, S. Marchand-Adam, G. Prévot, B. Wallaert, E. Bergot, P. Camus, J.-C. Dalphin, C. Dromer, E. Gomez, D. Israel-Biet, S. Jouneau, R. Kessler, C.-H. Marquette, M. Reynaud-Gaubert, B. Aguilaniu, D. Bonnet, P. Carré, C. Danel, J.-B. Faivre, G. Ferretti, N. Just, F. Lebargy, B. Philippe, P. Terrioux, F. Thivolet-Béjui, B. Trumbic, and D. Valeyre

Subjects
Pulmonary and Respiratory Medicine
Published
2017
Full Text
View/download PDF

9. RETRAIT: Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2017. Version courte

Author

V. Cottin, B. Crestani, J. Cadranel, J.-F. Cordier, S. Marchand-Adam, G. Prévot, B. Wallaert, E. Bergot, P. Camus, J.-C. Dalphin, C. Dromer, E. Gomez, D. Israel-Biet, S. Jouneau, R. Kessler, C.-H. Marquette, M. Reynaud-Gaubert, B. Aguilaniu, D. Bonnet, P. Carré, C. Danel, J.-B. Faivre, G. Ferretti, N. Just, F. Lebargy, B. Philippe, P. Terrioux, F. Thivolet-Béjui, B. Trumbic, and D. Valeyre

Subjects
Pulmonary and Respiratory Medicine, 03 medical and health sciences, Idiopathic pulmonary fibrosis, 0302 clinical medicine, 030228 respiratory system, business.industry, Medicine, 030212 general & internal medicine, Short length, business, medicine.disease, Nuclear medicine
Published
2017
Full Text
View/download PDF

10. Validation préliminaire d’un questionnaire de dépistage des entorses externes bénignes récentes de la cheville conçu à l’attention des pharmaciens officinaux

Author

B. Trumbic, J. Rodineau, J.J. Banihachemi, M. Baumgarten, Henri Partouche, E. Hodaj, N. Gonnet, and Jean-Luc Cracowski

Subjects
Rehabilitation, Orthopedics and Sports Medicine, Surgery
Abstract

Resume Introduction Nous avons elabore un questionnaire visant a aider le diagnostic positif des entorses externes benignes recentes de la cheville (questionnaire EEBRC) par les pharmaciens officinaux. Objectif Analyser les qualites metriques du questionnaire EEBRC. Methodes La performance diagnostique d’un ensemble de 10 questions (items), regroupees dans une section « examen initial » du questionnaire EEBRC, a ete testee comparativement aux donnees d’une etude prospective randomisee de 388 patients pris en charge aux urgences traumatologiques pour une entorse externe de la cheville (cohorte TALOS). Dans cette derniere, apres un suivi de 1 an, le diagnostic final d’entorse benigne, moyenne et grave de la cheville a ete pose chez respectivement 28 %, 22 % et 38 % des patients, 12 % presentant un diagnostic differentiel. Resultats Le questionnaire a 10 items avait une specificite de 98,6 % ; une specificite comparable (98,4 %) etait conservee par une version simplifiee a 7 items. La sensibilite de ces deux versions etait de 1,7 % et 1,5 % respectivement. Le meilleur equilibre entre specificite et sensibilite (86,7 % et 29,2 %, respectivement) etait associe a une version a 5 items. Conclusions En raison de la haute specificite du questionnaire EEBRC a 7 items, un resultat positif permet d’affirmer le diagnostic d’entorse externe benigne de la cheville avec un risque d’erreur faible. Ce questionnaire n’est pas adapte a la reconnaissance et a la classification de toutes les categories de gravite de l’entorse. De futures etudes visant a affiner ce questionnaire et a tester prospectivement sa validation en conditions reelles d’utilisation meritent d’etre realisees.

Published
2014
Full Text
View/download PDF

11. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version

Author

Françoise Thivolet-Béjui, Gilbert Ferretti, D. Bonnet, G. Prévot, N. Just, Vincent Cottin, Jean-Charles Dalphin, Philippe Camus, P. Terrioux, Jean-Baptiste Faivre, Dominique Israel-Biet, Bruno Crestani, Sylvain Marchand-Adam, B. Trumbic, Bernard Aguilaniu, Charles-Hugo Marquette, Jean-François Cordier, Ronald C. Kessler, Martine Reynaud-Gaubert, Jacques Cadranel, Philippe Carré, Emmanuel Bergot, François Lebargy, Emmanuel Gomez, Dominique Valeyre, B. Philippe, Stéphane Jouneau, Benoit Wallaert, Claire Danel, Claire Dromer, Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL], Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of Pneumology [Lyon], Hospices Civils de Lyon (HCL), Service de Pneumologie A, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre de compétence des maladies pulmonaires rares, Service de Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pathologies Respiratoires : Protéolyse et Aérosolthérapie, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Pneumologie, Paris, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Nouvel Hôpital Civil Strasbourg, Centre Hospitalier Universitaire de Nice (CHU Nice), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Le CHCB, Centre Hospitalier de la Côte Basque, Centre Hospitalier de Carcassonne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier de Roubaix, Plasticité de l'épithélium respiratoire dans les conditions normales et pathologiques - UMR-S 903 (PERPMP), SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre Hospitalier Universitaire de Reims (CHU Reims)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Reims Champagne-Ardenne (URCA), Centre Hospitalier René Dubos [Pontoise], Centre Hospitalier de Meaux, Groupe Hospitalier Est, Centre de Pathologie Est, Service des maladies respiratoires, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Avicenne-Jean Verdier-René Muret, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Université Paris Diderot - Paris 7 (UPD7), Université Pierre et Marie Curie - Paris 6 (UPMC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Albert Calmette, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital JeanMinjoz, Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Hôpital Haut-Lévêque [CHU Bordeaux], Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Hôpital Nord [CHU - APHM], Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Centre Hospitalier de la Côte Basque (CHCB), CHU Grenoble, Centre Hospitalier Victor Provo, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Avicenne [AP-HP], Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-Institut National de la Santé et de la Recherche Médicale (INSERM)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), and Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)

Subjects
Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Biopsy, MEDLINE, Short length, Lung pathology, Bronchoalveolar Lavage, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Diagnosis, Differential, 03 medical and health sciences, Idiopathic pulmonary fibrosis, 0302 clinical medicine, X ray computed, medicine, Pulmonary Medicine, Humans, 030212 general & internal medicine, Lung, ComputingMilieux_MISCELLANEOUS, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, business.industry, medicine.disease, Idiopathic Pulmonary Fibrosis, 3. Good health, 030228 respiratory system, Evidence-Based Practice, Radiography, Thoracic, France, business, Tomography, X-Ray Computed, Algorithms
Abstract

International audience; no abstract

Published
2017
Full Text
View/download PDF

12. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis: 2017 update. Summary

Author

G. Prévot, Philippe Carré, Charles-Hugo Marquette, Gilbert Ferretti, Claire Dromer, Emmanuel Bergot, Sylvain Marchand-Adam, P. Terrioux, Jacques Cadranel, Philippe Camus, Jean-Baptiste Faivre, D. Bonnet, Bruno Crestani, B. Trumbic, Dominique Valeyre, Dominique Israel-Biet, Jean-François Cordier, B. Philippe, François Lebargy, Ronald C. Kessler, Stéphane Jouneau, Bernard Aguilaniu, Benoit Wallaert, N. Just, Vincent Cottin, J.-C. Dalphin, Claire Danel, Françoise Thivolet-Béjui, Emmanuel Gomez, Martine Reynaud-Gaubert, Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL], Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of Pneumology [Lyon], Hospices Civils de Lyon (HCL), Physiopathologie et Epidemiologie de l'Insuffisance Respiratoire, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pneumologie A, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre de compétence des maladies pulmonaires rares, Département Hospitalo-universtaire FIRE (Fibrosis, Inflammation and Remodeling), LabEx Inflamex, Service de pneumologie A, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Bichat, Service de Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Theranoscan, Université Pierre et Marie Curie - Paris 6 (UPMC), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Pathologies Respiratoires : Protéolyse et Aérosolthérapie, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Pneumologie, Paris, Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Nouvel Hôpital Civil Strasbourg, Centre Hospitalier Universitaire de Nice (CHU Nice), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Le CHCB, Centre Hospitalier de la Côte Basque, Centre Hospitalier de Carcassonne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier de Roubaix, Plasticité de l'épithélium respiratoire dans les conditions normales et pathologiques - UMR-S 903 (PERPMP), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-Institut National de la Santé et de la Recherche Médicale (INSERM)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), Centre Hospitalier René Dubos [Pontoise], Centre Hospitalier de Meaux, Groupe Hospitalier Est, Centre de Pathologie Est, Service des maladies respiratoires, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Avicenne-Jean Verdier-René Muret, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier de la Côte Basque (CHCB), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), SFR CAP Santé (Champagne-Ardenne Picardie Santé), and Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre Hospitalier Universitaire de Reims (CHU Reims)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Reims Champagne-Ardenne (URCA)

Subjects
Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Biopsy, MEDLINE, Lung pathology, 030218 nuclear medicine & medical imaging, Diagnosis, Differential, 03 medical and health sciences, Idiopathic pulmonary fibrosis, 0302 clinical medicine, X ray computed, Pulmonary Medicine, Humans, Medicine, Lung, ComputingMilieux_MISCELLANEOUS, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, business.industry, medicine.disease, Idiopathic Pulmonary Fibrosis, 3. Good health, 030228 respiratory system, Evidence-Based Practice, Radiography, Thoracic, France, Tomography, X-Ray Computed, business, Algorithms
Abstract

International audience; no abstract

Published
2017
Full Text
View/download PDF

13. Is the Choosing Wisely® campaign model applicable to the management of multiple sclerosis in France? A GRESEP pilot study

Author

J. de Seze, B. Trumbic, E. Le Page, Hélène Zéphir, David-Axel Laplaud, C. Bensa, Jean-Christophe Ouallet, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), and Le Bihan, Sylvie

Subjects
medicine.medical_specialty, Urinary infection, Asymptomatic, Practice guidelines, Multiple sclerosis, 03 medical and health sciences, 0302 clinical medicine, Health care, medicine, In patient, 030212 general & internal medicine, Intensive care medicine, National health, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Cost control, Management of multiple sclerosis, medicine.disease, Focus group, 3. Good health, Neurology, Unnecessary procedures, Neurology (clinical), medicine.symptom, business, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Decision-making
Abstract

International audience; BACKGROUND: Launched in the US in 2012, Choosing Wisely® is a campaign promoted by the American Board of Internal Medicine (ABIM) Foundation with the goal of improving healthcare effectiveness by avoiding wasteful or unnecessary medical tests, treatments and procedures. It uses concise recommendations produced by national medical societies to start discussions between physicians and patients on the relevance of these services as part of a shared decision-making process. The Multiple Sclerosis Focus Group (Groupe de Reflexion Autour de la Sclérose en Plaques; GRESEP) undertook a pilot study to assess the relevance and feasibility of this approach in the management of multiple sclerosis (MS) in France.METHODS: Recommendations were developed using the formal consensus method from the guidelines of the French National Health Authority (HAS). A steering committee selected the themes and drafted concise evidence reviews. An independent rating group then assessed these recommendations for clarity, relevance and feasibility.RESULTS: Seven recommendations were accepted: (1) avoid systematic ordering of multimodal evoked potential studies for diagnosing MS; (2) do not treat MS relapses with low-dose oral corticosteroids; (3) when treating MS relapse with high-dose corticosteroids, the systematic use of the intravenous route is unnecessary if the oral route can be used; (4) systematic hospitalization is not necessary for treating MS relapse with high-dose corticosteroid therapy, particularly if the oral route is used, except for the first treated relapse and the presence of exclusion or non-eligibility criteria; (5) in the absence of clinical signs or symptoms of urinary infection, avoid systematic screening with urine microscopy and culture before the administration of corticosteroid therapy for MS relapse in patients using intermittent self-catheterization; (6) avoid antibiotic treatment of clinically asymptomatic MS patients using intermittent self-catheterization, even if urine microscopy and culture reveal the presence of microorganisms; and (7) avoid introducing symptomatic drug treatment for MS-related fatigue.CONCLUSION: This pilot study, the first of its kind in France, has demonstrated the relevance and feasibility of adapting the Choosing Wisely® model to MS by practitioners specializing in the disorder. However, the acceptability of these recommendations by other practitioners in other specialist fields as well as their impact on everyday clinical practices now need to be studied.

Published
2017
Full Text
View/download PDF

14. Is the Choosing Wisely

Author

B, Trumbic, H, Zéphir, J-C, Ouallet, E, Le Page, D, Laplaud, C, Bensa, and J, de Sèze

Subjects
Multiple Sclerosis, Patients, Decision Making, Disease Management, Guidelines as Topic, Pilot Projects, Unnecessary Procedures, Urinalysis, Adrenal Cortex Hormones, Recurrence, Physicians, Feasibility Studies, Humans, France, Patient Participation
Abstract

Launched in the US in 2012, Choosing WiselyRecommendations were developed using the formal consensus method from the guidelines of the French National Health Authority (HAS). A steering committee selected the themes and drafted concise evidence reviews. An independent rating group then assessed these recommendations for clarity, relevance and feasibility.Seven recommendations were accepted: (1) avoid systematic ordering of multimodal evoked potential studies for diagnosing MS; (2) do not treat MS relapses with low-dose oral corticosteroids; (3) when treating MS relapse with high-dose corticosteroids, the systematic use of the intravenous route is unnecessary if the oral route can be used; (4) systematic hospitalization is not necessary for treating MS relapse with high-dose corticosteroid therapy, particularly if the oral route is used, except for the first treated relapse and the presence of exclusion or non-eligibility criteria; (5) in the absence of clinical signs or symptoms of urinary infection, avoid systematic screening with urine microscopy and culture before the administration of corticosteroid therapy for MS relapse in patients using intermittent self-catheterization; (6) avoid antibiotic treatment of clinically asymptomatic MS patients using intermittent self-catheterization, even if urine microscopy and culture reveal the presence of microorganisms; and (7) avoid introducing symptomatic drug treatment for MS-related fatigue.This pilot study, the first of its kind in France, has demonstrated the relevance and feasibility of adapting the Choosing Wisely

Published
2016

16. Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid

Author

J. L. Misset, E. Ecstein, B. Trumbic, J.M. Lang, L. Bonhomme, C. Jasmin, G Fredj, S. Averous, A. M. Szekely, and P Meyer

Subjects
Adult, Male, Skin Neoplasms, Letter to the editor, business.industry, Remission Induction, Retinoic acid, All trans, HIV Infections, Tretinoin, Topical treatment, Hematology, Middle Aged, Virology, chemistry.chemical_compound, Oncology, chemistry, Humans, Medicine, Epidemic Kaposi's sarcoma, business, Sarcoma, Kaposi, Neoplasm Staging
Published
1991
Full Text
View/download PDF

18. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version.

Author

Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, and Terrioux P

Subjects
Humans, Lung pathology, Prognosis, Tomography, X-Ray Computed methods, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis epidemiology, Idiopathic Pulmonary Fibrosis therapy, Lung Transplantation
Abstract

Background: Since the latest 2017 French guidelines, knowledge about idiopathic pulmonary fibrosis has evolved considerably., Methods: Practical guidelines were drafted on the initiative of the Coordinating Reference Center for Rare Pulmonary Diseases, led by the French Language Pulmonology Society (SPLF), by a coordinating group, a writing group, and a review group, with the involvement of the entire OrphaLung network, pulmonologists practicing in various settings, radiologists, pathologists, a general practitioner, a health manager, and a patient association. The method followed the "Clinical Practice Guidelines" process of the French National Authority for Health (HAS), including an online vote using a Likert scale., Results: After a literature review, 54 guidelines were formulated, improved, and then validated by the working groups. These guidelines addressed multiple aspects of the disease: epidemiology, diagnostic procedures, quality criteria and interpretation of chest CT scans, lung biopsy indication and procedures, etiological workup, methods and indications for family screening and genetic testing, assessment of the functional impairment and prognosis, indication and use of antifibrotic agents, lung transplantation, management of symptoms, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis., Conclusion: These evidence-based guidelines are intended to guide the diagnosis and practical management of idiopathic pulmonary fibrosis., Competing Interests: Declaration of Competing Interest None., (Copyright © 2022. Published by Elsevier Masson SAS.)

Published
2023
Full Text
View/download PDF

19. [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version].

Author

Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, and Terrioux P

Subjects
Biopsy, Humans, Lung pathology, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis epidemiology, Idiopathic Pulmonary Fibrosis therapy, Lung Transplantation, Pulmonary Medicine
Abstract

Background: Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated., Methods: Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients' association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale., Results: After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis., Conclusion: These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis., (Copyright © 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.)

Published
2022
Full Text
View/download PDF

20. [French practical guidelines for the diagnosis and management of IPF - 2021 update, short version].

Author

Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, and Terrioux P

Subjects
Humans, Lung pathology, Pulmonologists, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis epidemiology, Idiopathic Pulmonary Fibrosis therapy, Lung Transplantation, Pulmonary Medicine
Abstract

Background: Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated., Methods: Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients' association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale., Results: After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis., Conclusion: These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis., (Copyright © 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.)

Published
2022
Full Text
View/download PDF

21. Management of pain associated with up-to-9-weeks medical termination of pregnancy (MToP) using mifepristone-misoprostol regimens: expert consensus based on a systematic literature review.

Author

Fiala C, Agostini A, Bombas T, Cameron S, Lertxundi R, Lubusky M, Parachini M, Saya L, Trumbic B, and Gemzell Danielsson K

Subjects
Abortifacient Agents, Steroidal adverse effects, Abortifacient Agents, Steroidal pharmacology, Abortion, Induced methods, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Consensus, Female, Humans, Ibuprofen administration & dosage, Mifepristone adverse effects, Mifepristone pharmacology, Misoprostol adverse effects, Misoprostol pharmacology, Pregnancy, Pregnancy Trimester, First, Abortion, Induced adverse effects, Pain Management methods, Pain Measurement methods
Abstract

Evidence-based guidelines on the management of pain associated with first-trimester medical abortion are lacking. Most published clinical trials have failed to report on this important aspect of the procedure. The aim of this comprehensive work was to provide clinical advice based on a comprehensive literature review, supplemented by the clinical experience of a group of European experts in case no evidence is available. Pain level ranged from 5 to 8 in 80% of studies where pain was measured on a 0-10 visual analogue scale; severe pain was reported by 20-80% of women. Pain assessment was rarely reported in studies. Pain treatment should be preventive and avoidance of unnecessary uterine contractions should be considered. Analgesic treatment should follow the WHO three-step ladder, starting with the use of NSAIDs and allowing for easily available back-up treatment with weak opioids.

Published
2020
Full Text
View/download PDF

22. Minimally Invasive Aesthetic Treatment of the Face and Neck Using Combinations of a PCL-Based Collagen Stimulator, PLLA/PLGA Suspension Sutures, and Cross-Linked Hyaluronic Acid.

Author

de Melo F, Carrijo A, Hong K, Trumbic B, Vercesi F, Waldorf HA, and Zenker S

Abstract

Background: Combinations of minimally invasive procedures (MIPs) are often used in aesthetic treatments and are increasingly considered as the new standard of care. Three agents with specific properties are available in this perspective: a polycaprolactone (PCL)-based collagen stimulator, a poly-L-lactic acid (PLLA)- and a poly-glycolic acid (PLGA)-based resorbable suspension suture with a 3D-cone technology, and a cross-linked hyaluronic acid (HA)., Objective: To develop the first practice guidelines on rejuvenation treatment of the face and the neck using combinations of these agents, whether associated or not with other widely used MIPs such as botulinum neurotoxins or energy-based devices., Methods: A multi-disciplinary, multi-national board of plastic surgeons and dermatologists convened to develop guidelines using a predefined consensus method. The consensus was defined as ≥83% agreement rate between participants., Results: Practice guidelines and algorithms, describing optimal procedure sequence and spacing, are proposed for the treatment of upper-, mid-, lower-face and neck, combining the PCL collagen stimulator, the PLLA/PLGA suspension sutures, and the cross-linked HA, whether associated or not with other MIPs., Conclusion: These new guidelines provide general support to optimal management strategies. Individual treatment plans should be adapted according to the physician's individual competence and the patient's preferences., Competing Interests: Dr Francisco de Melo reports personal fees, non-financial support from Sinclair Pharma. Dr Alieksiéi Carrijo, Dr Kyungkook Hong, and Dr Bruno Trumbic report personal fees from Sinclair Pharma. Dr Franco Vercesi was the International Trainer and Key Opinion Leader for Sinclair Pharma. Dr Heidi A Waldorf reports being a honorarium advisory board member for Sinclair Pharma and reports personal fees from Allergan, Endo, Galderma, Merz, Revance, Sinclair Pharma, and Suneva. Dr Sabine Zenker reports personal fees from L’Oréal Paris, Merz, Mesoestetic, Quantificare, and Sinclair Pharma. The authors report no other conflicts of interest in this work., (© 2020 de Melo et al.)

Published
2020
Full Text
View/download PDF

23. Is the Choosing Wisely ® campaign model applicable to the management of multiple sclerosis in France? A GRESEP pilot study.

Author

Trumbic B, Zéphir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, and de Sèze J

Subjects
Adrenal Cortex Hormones administration & dosage, Adrenal Cortex Hormones therapeutic use, Decision Making, Feasibility Studies, France, Guidelines as Topic, Humans, Multiple Sclerosis diagnosis, Patient Participation, Patients, Physicians, Pilot Projects, Recurrence, Unnecessary Procedures, Urinalysis, Disease Management, Multiple Sclerosis therapy
Abstract

Background: Launched in the US in 2012, Choosing Wisely ® is a campaign promoted by the American Board of Internal Medicine (ABIM) Foundation with the goal of improving healthcare effectiveness by avoiding wasteful or unnecessary medical tests, treatments and procedures. It uses concise recommendations produced by national medical societies to start discussions between physicians and patients on the relevance of these services as part of a shared decision-making process. The Multiple Sclerosis Focus Group (Groupe de Reflexion Autour de la Sclérose en Plaques; GRESEP) undertook a pilot study to assess the relevance and feasibility of this approach in the management of multiple sclerosis (MS) in France., Methods: Recommendations were developed using the formal consensus method from the guidelines of the French National Health Authority (HAS). A steering committee selected the themes and drafted concise evidence reviews. An independent rating group then assessed these recommendations for clarity, relevance and feasibility., Results: Seven recommendations were accepted: (1) avoid systematic ordering of multimodal evoked potential studies for diagnosing MS; (2) do not treat MS relapses with low-dose oral corticosteroids; (3) when treating MS relapse with high-dose corticosteroids, the systematic use of the intravenous route is unnecessary if the oral route can be used; (4) systematic hospitalization is not necessary for treating MS relapse with high-dose corticosteroid therapy, particularly if the oral route is used, except for the first treated relapse and the presence of exclusion or non-eligibility criteria; (5) in the absence of clinical signs or symptoms of urinary infection, avoid systematic screening with urine microscopy and culture before the administration of corticosteroid therapy for MS relapse in patients using intermittent self-catheterization; (6) avoid antibiotic treatment of clinically asymptomatic MS patients using intermittent self-catheterization, even if urine microscopy and culture reveal the presence of microorganisms; and (7) avoid introducing symptomatic drug treatment for MS-related fatigue., Conclusion: This pilot study, the first of its kind in France, has demonstrated the relevance and feasibility of adapting the Choosing Wisely ® model to MS by practitioners specializing in the disorder. However, the acceptability of these recommendations by other practitioners in other specialist fields as well as their impact on everyday clinical practices now need to be studied., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)

Published
2018
Full Text
View/download PDF

24. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis: 2017 update. Summary.

Author

Cottin V, Crestani B, Cadranel J, Cordier JF, Marchand-Adam S, Prévot G, Wallaert B, Bergot E, Camus P, Dalphin JC, Dromer C, Gomez E, Israel-Biet D, Jouneau S, Kessler R, Marquette CH, Reynaud-Gaubert M, Aguilaniu B, Bonnet D, Carré P, Danel C, Faivre JB, Ferretti G, Just N, Lebargy F, Philippe B, Terrioux P, Thivolet-Béjui F, Trumbic B, and Valeyre D

Subjects
Algorithms, Biopsy, Diagnosis, Differential, Evidence-Based Practice standards, Evidence-Based Practice trends, France, Humans, Lung pathology, Pulmonary Medicine standards, Radiography, Thoracic, Tomography, X-Ray Computed, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis therapy, Pulmonary Medicine methods, Pulmonary Medicine trends
Published
2017
Full Text
View/download PDF

25. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version.

Author

Cottin V, Crestani B, Cadranel J, Cordier JF, Marchand-Adam S, Prévot G, Wallaert B, Bergot E, Camus P, Dalphin JC, Dromer C, Gomez E, Israel-Biet D, Jouneau S, Kessler R, Marquette CH, Reynaud-Gaubert M, Aguilaniu B, Bonnet D, Carré P, Danel C, Faivre JB, Ferretti G, Just N, Lebargy F, Philippe B, Terrioux P, Thivolet-Béjui F, Trumbic B, and Valeyre D

Subjects
Algorithms, Biopsy, Bronchoalveolar Lavage, Diagnosis, Differential, Evidence-Based Practice standards, Evidence-Based Practice trends, France, Humans, Lung pathology, Pulmonary Medicine standards, Radiography, Thoracic, Tomography, X-Ray Computed, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis therapy, Pulmonary Medicine methods, Pulmonary Medicine trends
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results